Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mineralys said the FDA accepted its NDA for lorundrostat in Q1, marking a key step toward approval for a drug aimed at uncontrolled and resistant hypertension. Management highlighted a differentiated package from five clinical trials showing consistent blood pressure benefit and a safety profile they believe fits current physician use cases. The addressable U.S. population was cited at about 20 million patients on two or more medications who still do not reach blood-pressure goals.

Analysis

MLYS is transitioning from a binary development story to a near-term commercialization/review story, which usually compresses the volatility regime rather than eliminating it. The main second-order effect is that the market should start pricing not just approval probability, but label quality, launch sequencing, and payer access — the stock can re-rate even before approval if the FDA review cadence and advisory-risk profile stay clean.

The underappreciated winner here is the hypertension ecosystem around resistant patients: if lorundrostat lands with a differentiated safety/efficacy profile, it can expand the treatable market rather than merely steal share from existing add-ons. That puts pressure on incumbent branded therapies that rely on the same late-line population, while also creating a portfolio effect for large pharma looking to fill cardiometabolic pipelines via M&A or licensing before commercialization risk is removed.

The key risk is that the story shifts from clinical consistency to regulatory and real-world execution. A modest delay in review, a request for additional data, or ambiguity around patient segmentation could cut the valuation multiple faster than a negative vote because the current setup likely embeds an approval and launch window within the next few quarters. Over a 3-6 month horizon, the stock is more sensitive to FDA process signals than to incremental clinical debate.

Contrarian view: consensus may be underestimating how much of the value is already concentrated in “approved eventually” and overestimating how smoothly launch economics translate in a crowded hypertension market. If payers push hard on step edits or prior auth, the addressable commercial opportunity could open more slowly than the clinical narrative implies, making this more of a staged rerating than a straight-line move.

Key Decisions for Investors

• Long MLYS into FDA-process milestones over the next 1-3 months; treat pullbacks tied to non-fundamental volatility as entry points. Risk/reward is favorable if the market continues to price a clean review path, but trim aggressively if review timing slips.
• Buy MLYS call spreads 3-6 months out to express approval upside with limited theta risk. Prefer upside structures over outright equity because the stock likely reprices on process signals before commercialization data.
• Pair long MLYS / short a basket of mature antihypertensive or late-line cardio names over 2-4 months to isolate regulatory rerating versus therapeutic-area beta. The trade works best if the market starts rewarding pipeline scarcity and clean path-to-market assets.
• Watch for M&A optionality in large pharma/cardiometabolic names; a confirmed differentiated profile would make MLYS a plausible tuck-in candidate. If that bid logic emerges, upside could extend beyond the base approval case.